News Sentiment

ATOS sentiment intelligence

Atossa Genetics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.37 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+11.8% over one week, -3.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Atossa Therapeutics Inc (ATOS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction 11.8% Price confirming higher
Trend fit Trend inactive -3.7% over four weeks
Fair value -82.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 35
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 8
Market source 6
Investing.com 6
Stock Titan 4
PR Newswire 4
MarketBeat 4
www.marketscreener.com 2
Investing.com Nigeria 2

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 12
Analyst action 4
Guidance 2
Balance sheet 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 53
TradingKey Direct company coverage

Atossa Therapeutics Inc (ATOS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Atossa Therapeutics Inc (ATOS) has an earnings forecast score of 8.00, placing it 170th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $5.50 for ATOS, with a "Buy" recommendation based on the ratings of two analysts. The company's p

Tone
Positive 63/100
Event
Earnings
Published
13 Jul 2026 02:10
Source
TradingKey
TradingView Direct company coverage

Price to sales forward of Atossa Therapeutics, Inc. – DUS:YAG

The article displays the "Price to sales forward" financial metric for Atossa Therapeutics, Inc. (Symbol: YAG) on the Dusseldorf Stock Exchange. It indicates no current trades as the market is closed. The content primarily provides navigation and informational links related to Tr

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 00:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Atossa Therapeutics, Inc. – DUS:YAG

This article focuses on the enterprise value to revenue forward for Atossa Therapeutics, Inc. (DUS:YAG). It provides a financial overview of the company as traded on the Dusseldorf Stock Exchange. The content appears to be a stub or a section of a larger financial data presentati

Tone
Neutral 50/100
Event
Earnings
Published
12 Jul 2026 18:10
Source
TradingView
TradingView Direct company coverage

Price to cash flow ratio of Atossa Therapeutics, Inc. – DUS:YAG

This page provides financial data, specifically the price to cash flow ratio, for Atossa Therapeutics, Inc. (YAG) on the Dusseldorf Stock Exchange. It notes that the market is currently closed with no trades. The content primarily outlines the financial overview and related servi

Tone
Neutral 50/100
Event
Balance sheet
Published
09 Jul 2026 12:10
Source
TradingView
GuruFocus Direct company coverage

ATOS Initiates Coverage On Rodman & Renshaw -- Rating Set to Buy

Rodman & Renshaw has initiated coverage on Atossa Therapeutics (ATOS) with a Buy rating and a $12.00 price target. Despite a strong financial standing (9/10), the company faces challenges in profitability and growth, reflected in its GF Score™ of 26/100. Investors are advised to

Tone
Positive 63/100
Event
Analyst action
Published
07 Jul 2026 18:11
Source
GuruFocus
Investing.com South Africa Direct company coverage

Rodman & Renshaw initiates Atossa Genetics stock with buy rating By Investing.com

Rodman & Renshaw has initiated coverage on Atossa Genetics Inc. (NASDAQ:ATOS) with a buy rating and a $12.00 price target. The firm highlighted Atossa's estrogen receptor modulator, which shows clinical activity in breast cancer treatment and has validated clinical results, along

Tone
Positive 72/100
Event
Analyst action
Published
07 Jul 2026 14:11
Source
Investing.com South Africa
Finviz Direct company coverage

ATOS - Atossa Therapeutics Inc Short Interest

This article provides a detailed overview of Atossa Therapeutics Inc.'s (ATOS) financial data and stock performance, with a specific focus on its short interest. Key metrics include market capitalization, price-to-book ratio, EPS growth, insider and institutional ownership, and v

Tone
Negative 41/100
Event
Earnings
Published
07 Jul 2026 00:11
Source
Finviz
www.marketscreener.com Direct company coverage

Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell Microcap Value Benchmark Index

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) has been added to the Russell Microcap Value Benchmark Index. This inclusion follows its recent addition to the Russell 3000E Index, the Russell Microcap Index, and the Russell 3000E Growth Benchmark. The company is a clinical-stage bioph

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 13:40
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Atossa Therapeutics, Inc.(NasdaqCM: ATOS) added to Russell Microcap Index

Atossa Therapeutics, Inc. (NasdaqCM: ATOS) has been added to the Russell Microcap Index, as announced on June 29, 2026. This inclusion is significant for the clinical-stage biopharmaceutical company, which focuses on developing treatments for women’s breast cancer and other breas

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 09:09
Source
marketscreener.com
TradingView Direct company coverage

Price to book forward of Atossa Therapeutics, Inc. – NASDAQ:ATOS

This article provides financial information for Atossa Therapeutics, Inc. (NASDAQ: ATOS), specifically its "Price to book forward" metric. The content emphasizes that the market was closed at the time of publication, and no trades were made. It also lists various data sources and

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 06:11
Source
TradingView
www.marketscreener.com Direct company coverage

Atossa Therapeutics, Inc.(NasdaqCM: ATOS) added to Russell 3000E Growth Benchmark

Atossa Therapeutics, Inc. (ATOS) has been included in the Russell 3000E Growth Benchmark. This addition highlights the clinical-stage biopharmaceutical company's progress in developing medicines for unmet medical needs in oncology, particularly focusing on breast cancer with its

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 04:11
Source
www.marketscreener.com
TradingView Direct company coverage

Price to sales forward of Atossa Therapeutics, Inc. – MUN:YAG

This page provides financial information for Atossa Therapeutics, Inc. (MUN:YAG), specifically focusing on its forward price-to-sales ratio. It indicates that the market for this stock was closed with no trades recorded at the time of viewing. The content appears to be a financia

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 09:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Atossa Therapeutics, Inc. – MUN:YAG

This article provides financial information for Atossa Therapeutics, Inc. (MUN:YAG) listed on the Munich Stock Exchange, specifically focusing on its Price to Earnings Forward metric. The content highlights the company's financial data and is presented within the TradingView plat

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 08:11
Source
TradingView
TradingView Direct company coverage

Price to book forward of Atossa Therapeutics, Inc. – MUN:YAG

This article displays the price to book forward metric for Atossa Therapeutics, Inc. (MUN:YAG) on the Munich Stock Exchange. It notes the market is currently closed with no trades. The information is presented within the TradingView platform context.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 08:09
Source
TradingView
Simply Wall Street Direct company coverage

Atossa Therapeutics, Inc. (NASDAQ:ATOS): Are Analysts Optimistic?

Atossa Therapeutics (NASDAQ:ATOS), a clinical-stage biopharmaceutical company, is expected by analysts to reach profitability in 2028, after incurring a loss of US$38m in the latest trailing-twelve-month period. This breakeven projection relies on a very high average annual growt

Tone
Positive 62/100
Event
Guidance
Published
25 Jun 2026 10:39
Source
Simply Wall Street
Investing.com Nigeria Direct company coverage

Atossa Therapeutics raises $4.5M in registered direct offering By Investing.com

Atossa Therapeutics has announced a registered direct offering to institutional investors, aiming to raise approximately $4.5 million in gross proceeds. The offering involves the sale of common stock and warrants, with potential for an additional $12 million if warrants are fully

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 16:11
Source
Investing.com Nigeria
BioSpace Direct company coverage

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics announced the closing of a registered direct offering, generating approximately $4.5 million in gross proceeds upfront, with the potential for an additional $12 million from warrant exercises. The offering involved shares of common stock and Series A and Serie

Tone
Positive 61/100
Event
Market update
Published
14 Jun 2026 13:48
Source
BioSpace
Investing.com Nigeria Direct company coverage

Atossa Therapeutics closes $4.5M registered direct offering By Investing.com

Atossa Therapeutics recently completed a registered direct offering, securing $4.5 million in gross proceeds. This financing involved the sale of common stock and warrants, which could bring in an additional $12 million if fully exercised. The company plans to use these funds for

Tone
Neutral 50/100
Event
Market update
Published
13 Jun 2026 01:39
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Cancer-drug developer Atossa raises $4.5M, eyes $12M more

Atossa Therapeutics has closed a registered direct offering, securing approximately $4.5 million in gross proceeds from the sale of common shares and warrants. The offering also provides the potential for an additional $12 million if all Series Warrants are fully exercised. The c

Tone
Negative 40/100
Event
Market update
Published
13 Jun 2026 01:09
Source
Stock Titan
Investing.com Direct company coverage

Atossa Therapeutics closes $4.5M registered direct offering

Atossa Therapeutics, Inc. has successfully completed a registered direct offering, securing approximately $4.5 million in gross proceeds. The biopharmaceutical company sold common stock and warrants, which could bring in an additional $12 million if fully exercised. Atossa plans

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 22:09
Source
Investing.com
Pulse 2.0 Direct company coverage

Atossa Therapeutics Announces Up To $16.5 Million Registered Direct Offering

Atossa Therapeutics has announced a registered direct offering with institutional investors, expected to generate $4.5 million upfront and potentially up to $16.5 million if warrants are fully exercised. The offering includes common stock and Series A and B warrants, with proceed

Tone
Positive 65/100
Event
Market update
Published
12 Jun 2026 20:39
Source
Pulse 2.0
Stock Titan Direct company coverage

Atossa Therapeutics (NASDAQ: ATOS) sells 1.36M shares with warrants in $4.5M deal

Atossa Therapeutics is conducting a registered direct offering to sell 1,363,637 shares of common stock, each combined with one Series A warrant and one Series B warrant, at an offering price of $3.30 per share, aiming for gross proceeds of $4,500,002.10 and estimated net proceed

Tone
Neutral 50/100
Event
Deals and strategy
Published
12 Jun 2026 13:09
Source
Stock Titan
Investing.com Direct company coverage

Atossa Therapeutics stock tumbles on $4.5M stock offering

Atossa Therapeutics Inc. (NASDAQ: ATOS) shares fell 30% in premarket trading after announcing a registered direct offering expected to raise $4.5 million. The company entered into an agreement with institutional investors to sell 1,363,638 shares of common stock at $0.18 par valu

Tone
Negative 14/100
Event
Market update
Published
11 Jun 2026 13:09
Source
Investing.com
Investing.com Direct company coverage

Atossa Therapeutics raises $4.5M in registered direct offering

Atossa Therapeutics, Inc. announced a registered direct offering raising approximately $4.5 million in gross proceeds. The clinical-stage biopharmaceutical company is selling over 1.3 million shares and accompanying warrants, with potential for an additional $12 million if warran

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 12:40
Source
Investing.com